Androgenetic Alopecia (AGA)NCT07551271
Clinical Study of PRP in the Treatment of Androgenetic Alopecia
A study testing PRP in people with Androgenetic Alopecia (AGA), run by The First Affiliated Hospital of Soochow University at 1 site in China.
Trial summary
A study on the therapeutic effect of platelet-rich plasma in the treatment of androgenetic alopecia Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Androgenetic Alopecia (AGA)
- What is being tested?
- PRP
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2025to 1 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- moderate to severe androgenic Alopecia
Who cannot join
- abnormal coagulation
Trial locations and contacts
1 site in 1 country.
China1 site
the First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215300
About this study
Official title: The Application of Platelet-rich Plasma in the Treatment of Androgenic Alopecia：a Prospective Clinical Random Study.
A study on the therapeutic effect of platelet-rich plasma in the treatment of androgenetic alopecia
Read the detailed description
This study included 30 patients with moderate and severe androgenic alopecia and randomly divided into two groups, group A was treated with platelet-rich plasma (once 4 weeks for 3 times) combined with external Minoxidil(5% for male, 2% for female, twice a day, 1 ml each time) , group B was treated with external Minoxidil. The patients in both groups were examined by dermoscopy before the first treatment and 1,2,3 and 6 months after the treatment. The scalp MRI was performed before the first treatment and 6 months after the treatment, the number, density and depth of hair follicles were measured to evaluate the efficacy and safety of platelet-rich plasma combined with Minoxidil in the treatment of androgenic alopecia.
- Conditions
- Androgenetic Alopecia (AGA)
- Being tested
- PRP
- Keywords
- Androgenetic alopecia, Platelet-rich plasma, Minoxidil, Dermoscpe
- Medical subject headings
- Alopecia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PRPDrug
Also called plitelet-rich plasma
group A was treated with platelet-rich plasma combined with external Minoxidil , group B was treated with external Minoxidil
| Study group | Role | What they receive |
|---|---|---|
| group A | Experimental | platelet-rich plasma combined with minoxidil Receives: Drug: PRP |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dermoscope
The amount of hair on the parietal and posterior occipital regions
Measured: before the first treatment and 1,2,3 and 6 months after the treatment
MRI
Hair follicle density on the parietal and posterior occipital regions
Measured: before the first treatment and 6 months after the treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2026
- Study start1 Jan 2025
- Primary completion1 Jan 2026
- Study completion1 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Androgenetic Alopecia (AGA)Studies of the same condition, open and under way.
- More trials run by The First Affiliated Hospital of Soochow UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07551271
- Sponsor's protocol ID
- 20250315
- Status last verified
- Apr 2026
- First submitted
- 19 Apr 2026
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Application of Platelet-rich Plasma in the Treatment of Androgenic Alopecia：a Prospective Clinical Random Study.
- ClinicalTrials.gov ID
- NCT07551271
- Acronym / sponsor ID
- 20250315
- Conditions
- Androgenetic Alopecia (AGA)
- Keywords
- Androgenetic alopecia, Platelet-rich plasma, Minoxidil, Dermoscpe
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- The First Affiliated Hospital of Soochow UniversityUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 1 Jan 2026 (actual)
- Study completion
- 1 Mar 2026 (actual)
- First posted
- 24 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A study on the therapeutic effect of platelet-rich plasma in the treatment of androgenetic alopecia
Detailed description
This study included 30 patients with moderate and severe androgenic alopecia and randomly divided into two groups, group A was treated with platelet-rich plasma (once 4 weeks for 3 times) combined with external Minoxidil(5% for male, 2% for female, twice a day, 1 ml each time) , group B was treated with external Minoxidil. The patients in both groups were examined by dermoscopy before the first treatment and 1,2,3 and 6 months after the treatment. The scalp MRI was performed before the first treatment and 6 months after the treatment, the number, density and depth of hair follicles were measured to evaluate the efficacy and safety of platelet-rich plasma combined with Minoxidil in the treatment of androgenic alopecia.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| group A | Experimental | Drug: PRPplatelet-rich plasma combined with minoxidil |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- moderate to severe androgenic Alopecia
Key exclusion criteria (1 listed)
- abnormal coagulation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PRPAlso: plitelet-rich plasmagroup A was treated with platelet-rich plasma combined with external Minoxidil , group B was treated with external Minoxidil | Drug | group A |
Primary outcome
Dermoscope
Time frame: before the first treatment and 1,2,3 and 6 months after the treatment
The amount of hair on the parietal and posterior occipital regions
MRI
Time frame: before the first treatment and 6 months after the treatment
Hair follicle density on the parietal and posterior occipital regions
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Androgenetic Alopecia (AGA)
Not yet recruitingPhase 2
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
Androgenetic Alopecia
Not yet recruitingPhase 3
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Not yet recruiting
Study to Evaluate Xtressé Gummy Supplement in Women With Thinning Hair
Androgenetic Alopecia
Not yet recruitingEarly Phase 1
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
Androgenic Alopecia
Not yet recruitingPhase 3
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PRP in people with Androgenetic Alopecia (AGA), run by The First Affiliated Hospital of Soochow University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dermoscope (time frame: before the first treatment and 1,2,3 and 6 months after the treatment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.